Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

SWTX - SpringWorks Therapeutics, Inc.

IEX Last Trade
36.83
1.230   3.340%

Share volume: 0
Last Updated: Tue 24 Dec 2024 06:18:10 PM CET
Research and Development in Biotechnology (except Nanobiotechnology): 35.29%

PREVIOUS CLOSE
CHG
CHG%
$35.60
1.23
3.46%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
21%
Profitability 25%
Dept financing 1%
Liquidity 50%
Performance 15%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
3.43%
1 Month
-6.55%
3 Months
13.23%
6 Months
1.13%
1 Year
3.31%
2 Year
58.80%
Key data
Stock price
$36.83
P/E Ratio 
0.00
DAY RANGE
$35.60 - $37.22
EPS 
$0.00
52 WEEK RANGE
$29.14 - $53.92
52 WEEK CHANGE
-$0.62
MARKET CAP 
3.098 B
YIELD 
N/A
SHARES OUTSTANDING 
74.273 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
BETA 
1.45
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$1,249,754
AVERAGE 30 VOLUME 
$1,030,400
Company detail
CEO: Saqib Islam
Region: US
Website: springworkstx.com
Employees: 230
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors.

Recent news